As a biopharmaceutical manufacturer, you would like to carry out an analysis of disulfide bridges
What is a disulfide bridge?
A disulfide bridge is a covalent bond formed between two sulfur atoms belonging to cysteine residues within a protein or peptide. These bonds are essential to the three-dimensional stability of biomolecules, influencing their structure, biological activity and resistance to environmental conditions. Alterations to disulphide bridges can compromise the efficacy and safety of a product, particularly in the biopharmaceutical and biotechnology sectors.
Why analyse the disulfide bridges?
FILAB supports biopharmaceutical companies in the analysis of disulphide bridges
Why choose FILAB for disulfide bridge analysis?
FILAB, a laboratory of analytical expertise, offers comprehensive services for disulphide bridge analysis. We offer a range of customised methods to assess the properties of proteins and peptides, tailored to the specific needs of each customer.
Our disulfide bridge analysis services
Mapping disulfide bridges in recombinant proteins
Study of the stability of disulphide bridges under oxidative stress
Verification of the stability of disulfide bridges in a peptide
Localization and analysis of free sulfhydryl groups by HRMS
Quantification of disulfide bridges in monoclonal antibodies (mAbs)
Detection of anomalies in the formation of disulfide bridges
Comparative study of formulations to guarantee the integrity of disulfide bridges
Our FAQ
Disulfide bridge analysis consists of identifying the covalent bridge between two cysteine residues within a protein. This characterization is essential because these bridges stabilize the protein's three-dimensional structure (conformation), thereby determining its biological activity and stability.
The correct formation of disulfide bridge ensures that the recombinant protein possesses the proper tertiary structure. Misfolding or incorrect pairings can:
Alter the product's therapeutic efficacy.
Lead to drug instability.
Increase the risk of immunogenicity (adverse patient reactions).
Yes. According to ICH Q6B guidelines, the complete characterization of proteins includes determining the primary structure, which includes evidencing disulfide bonds. This is a mandatory step for the validation of registration dossiers for biopharmaceutical products (MA/Marketing Authorization).
The FILAB laboratory works with a wide range of complex biological molecules:
Monoclonal Antibodies (mAbs).
Recombinant proteins and glycoproteins.
Synthetic peptides and hormones.
Antibody-Drug Conjugates (ADCs).